KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: This resulted in an increased NK cell activation (CD69, NKp30, NKp44, NKG2D) as well as an increased tumor-directed cytotoxicity against chronic myeloid leukemia (CML) blasts and the leukemia cell line K562 compared to those NK cells stimulated without slanMo (63, 65).